Introduction
Long-acting bronchodilators, whether β 2 agonists (LABAs) or muscarinic antagonists (LAMAs), are central to symptom management in patients with COPD. 1 As well as improving lung function and health-related quality of life (HRQoL), they help prevent exacerbations and increase exercise endurance by reducing pulmonary hyperinflation 908 rodrigo et al and dyspnea. 2 LABA/inhaled corticosteroid (ICS) combinations are indicated for patients with severe-to-very-severe COPD and a history of repeated exacerbations. Despite these indications, however, LABA/ICS combinations remain the second-most commonly prescribed first-line treatments (after LAMA monotherapy) across the range of COPD severities. 3, 4 The use of LABA/ICS combinations has been associated with a decrease in the rate of COPD exacerbations but with an increased risk of pneumonia. 5 LAMAs and LABAs achieve bronchodilation through different mechanisms: muscarinic antagonists block acetylcholine-mediated bronchoconstriction by binding to M 3 receptors in airway smooth muscle, 6 whereas β 2 agonists induce smooth muscle relaxation by stimulating β 2 -adrenergic receptors. 7, 8 These distinct mechanisms result in differences in observed efficacy between the two classes of bronchodilators. Hence, some data suggest that LABAs are more effective at improving symptoms and HRQoL than LAMAs, while LAMAs are superior to LABAs in reducing exacerbations, with the differential efficacy likely occurring through modes of action beyond bronchodilation. [8] [9] [10] [11] [12] Such differences provide the opportunity of combining LABAs and LAMAs in an attempt to improve treatment outcomes.
Accumulating evidence from randomized controlled trials (RCTs) has shown that LABA/LAMA fixed-dose combinations (FDCs) have beneficial effects on lung function and patient-reported outcomes compared with LAMA or LABA/ICS treatments, while demonstrating a similar safety profile. [13] [14] [15] In a recent network meta-analysis, LABA/LAMA combinations have also been shown to be more effective than either of the monotherapy component in improving lung function, QoL, symptom scores and exacerbation rates while maintaining similar safety profiles. 16 Building on this, the aim of this meta-analysis was to compare the pooled efficacy and safety data from trials of FDCs of LABA/LAMAs with the two most commonly prescribed first-line treatments: LAMAs and LABA/ICS combinations.
Materials and methods literature search and terms used
Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines were used to perform this systematic review. 17 Full details are provided in the online Supplementary materials.
Inclusion criteria and outcome assessments
Randomized, parallel-group, controlled design of 4 weeks' duration, which compared LABA/LAMA FDCs with LAMA monotherapy or LABA/ICS combinations, were included. The studies were to have been conducted in adult patients aged 40 years with stable, moderate-to-very severe COPD. 1 Study treatments were restricted to all currently available LABA/LAMA combinations at the approved doses of these combinations and their comparators (in the US or EU; Table S1 ).
Studies were required to report at least one of the following outcomes: trough and/or peak FEV 1 ; transitional dyspnea index (TDI) total score; St George's Respiratory Questionnaire (SGRQ) total score; rescue medication use (puffs/day); COPD exacerbations (as a study end point); safety (frequency of adverse events [AEs], serious AEs [SAEs] and cardiovascular events); pneumonia incidence; withdrawal from treatment (due to AEs or lack of efficacy); or deaths while on treatment.
The primary outcome was trough FEV 1 ; secondary outcomes included peak FEV 1 , TDI, SGRQ, rescue medication use, prospectively collected annualized rate of COPD exacerbations, AEs and related safety measures. The effect of treatments was established at weeks 12, 24 or 26, and 52 (dependent on the trial) for efficacy end points, as well as throughout the trial duration for safety outcomes. In addition, in studies in which the data were evaluated, the proportions of patients who achieved minimal clinically important differences (MCIDs) in FEV 1 , TDI and SGRQ have also been presented; these are defined as a 100 mL increase over baseline for FEV 1 , 18 a 1 unit increase in TDI, 19 and a 4 unit decrease in SGRQ score. 20 
Data extraction and risk of bias assessment
Two authors (GJR and DP) reviewed the search results for relevant article titles meeting the inclusion criteria. The reviewers worked independently during study selection and data extraction; disagreements, if any, were resolved by discussion to obtain consensus.
Risk of bias of eligible trials was assessed by applying the Cochrane collaborations tool; 21 further details are provided in the online Supplementary materials.
Data analysis
The meta-analysis was performed using Review Manager, version 5.3.5 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) as described in detail in the online Supplementary materials. In all analyses, the P-values were based on a two-tailed test with P0.05 considered statistically significant. 
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laBa/laMa versus laMa monotherapy or laBa/ICs in COPD Outcomes were pooled as forest plots using mean differences (inverse variance [IV] or generic IV method), Mantel-Haenszel risk ratios (RRs) or risk differences (RDs). Precision of the estimates was quantified with 95% confidence intervals (CIs), and heterogeneity was assessed using the I 2 test. 22 Random-effects models were used to address variations across studies. 23 
Results

studies included in the analyses
The study selection process is described in Figure 1 , with further details supplied in the online Supplementary materials. Eighteen studies (comprising 23 clinical trials in total) fulfilled the eligibility criteria, and all were included in the analysis (N=20,185); both reviewers were in full agreement as to their inclusion. Details of the studies are summarized in Table 1 ; five comprised pooled data from two clinical trials. One of four pharmaceutical companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis) sponsored each of the studies, all of which involved randomized comparisons of approved doses of COPD treatments or placebo. Twelve of the studies compared LABA/LAMA with LAMA, 7, 15, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] while six compared LABA/LAMA with LABA/ICS (salmeterol/fluticasone propionate); [34] [35] [36] [37] [38] [39] two of the trials 25, 26 included two or more comparators. Further details for each of the studies can be found at https://ClinicalTrials. gov/ or in their respective primary publications. 7, 15, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Most of the studies showed a low risk of bias in the six items of the Cochrane instrument 21 (online Supplementary materials; Figures S1-S3 ).
effect of treatments on lung function (trough and peak FeV 1 )
The overall treatment effect for each of the treatment comparisons are shown in Table 2 for each outcome measure at each of the protocol-defined time points. At week 12, significant increases from baseline were observed in trough FEV 1 for the LABA/LAMAs indacaterol (Ind)/ glycopyrronium (Gly) (both dose regimens), umeclidinium (Umec)/vilanterol (Vi) and tiotropium (Tio)/olodaterol (Olo) Table 2 ; Figure S4 ). In addition, in studies where MCID was evaluated, 33% more patients receiving LABA/LAMA rather than LAMA treatments achieved the MCID in trough FEV 1 of 100 mL above baseline (RR: 1.33; 95% CI [1.20, 1.46]; Table 2 ). The number needed to treat to achieve this treatment benefit (NNTB) was 8 (95% CI [6, 9] ; Table 2 ). The absolute proportions of patients achieving any MCID were 58% (1,018 of 1,765) and 44% (978 of 2,240), respectively.
LABA/LAMA treatment also significantly increased trough FEV 1 Table 2 ), with an NNTB of 6 at week 12 (95% CI: [5, 7] ; Table 2 ). The absolute proportions of patients achieving any MCID (where evaluated) were 59% (803 of 1,371) and 41% (562 of 1,383), respectively.
Peak FEV 1 at week 12 and at weeks 24-26 was also higher in LABA/LAMA-treated patients versus both LAMAor LABA/ICS-treated patients (overall mean differences: 0.10-0.12 L; all P0.0001; Table 2; Figure S5 ).
effect of treatments on dyspnea, health status and rescue medication use
The effects of each treatment on dyspnea and health status (assessed by TDI and SGRQ, respectively), as well as rescue medication use, were determined at protocol-defined time points for individual trials and for treatment comparison subgroups. Overall treatment effects for all study subgroups combined are shown in Table 3 .
TDI focal score was significantly improved in LABA/ LAMA-versus LAMA-treated patients at weeks 12 and 24 (mean difference: 0. 5 Figure S6A ). Furthermore, in studies wherein it was evaluated, LABA/ Figure S6B ), although a trend in favor of LABA/LAMA treatment was observed.
With respect to the effect of different treatments on health status, SGRQ total scores (mean difference from baseline) at the week 12 and 24 time points were significantly improved in LABA/LAMA-versus LAMA-treated patients Figure S7A [iii]), although the direction of the treatment benefit remained in favor of LABA/ LAMA treatment. Furthermore, SGRQ scores at week 52 were only captured in three studies, compared with 11 and 8 in the earlier time points; therefore, this finding may not be as robust as the earlier time points because the end point was tested in a comparatively smaller population. Heterogeneity between the three trials comprising the week 52 end point was also relatively high, at an I 2 of 58%. In studies where MCID was evaluated, at the end of treatment, LABA/LAMA-treated Figure S7B ), an effect driven by the data of the Ind/Gly data available at that time point. Interestingly, the trial that contributed the greatest weight to the analysis of this comparison, FLAME, 36 was highly significantly in favor of LABA/LAMA at both time points (Figure S7B) .
At the end of treatment, rescue medication use relative to baseline use was significantly reduced in LABA/ LAMA-treated patients compared with those treated with either LAMA or LABA/ICS (reduction of -0.58 puffs/day, 95% CI: [-0 Figure S8 ).
effect of treatments on COPD exacerbations and hospitalizations
There were insufficient data to conduct a meta-analysis on the effect of treatment on prospectively collected COPD Figure 4A ). A trend in favor of LABA/LAMA was also observed for severe exacerbations alone, with one study 35 revealing a significant benefit in favor of LABA/ LAMA, and another 36 showing a numerical benefit. However, heterogeneity between the two studies was high for this end point, at I 2 =74% ( Figure 4B ).
effect of treatments on safety outcomes
The relative effects of each COPD treatment class on the safety end points of AE and SAE incidence, numbers of withdrawals (due to AEs or lack of efficacy) and deaths, as well as the effect of treatment on annualized exacerbation rate, are presented in Table 4 Figures S9B and S11B) .
The overall rates of death were low across treatment groups, with no significant differences observed between patients treated with LABA/LAMA and those on either LAMA or LABA/ICS (P=0.46 and 0.65, respectively; Table 4 ; Figure S12 ). Figure S14 ).
Discussion
In this meta-analysis of 23 RCTs in 20,185 patients with stable moderate-to-very severe COPD, we compared the efficacy and safety of dual bronchodilation with four The efficacy and safety of LABA/LAMA combinations has been evaluated in previous meta-analyses. 13, 14, 40 Single LABA/LAMA combinations have been evaluated in two studies, 13, 14 whereas in a recent meta-analysis, 40 all doses of LABA/LAMA combinations were pooled and treatment effects were compared with the combined pooled effect of the monocomponents (LABA or LAMA) and not with LABA/ ICS combinations. In our analysis, we also pooled the data from trials using the same treatments and dose regimens to facilitate comparisons between treatment subgroups. Pooling of data in this manner is recommended in meta-analyses in which there are only a few studies per subgroup because estimates within subgroups are likely to be imprecise; in such instances, the increased accuracy obtained using pooled estimates is likely to exceed any real differences between groups in the true value. The difference in our analysis compared with previous analyses is that we included all Abbreviations: AE, adverse event; CI, confidence interval; NNTH, number needed to treat for harm; ICS, inhaled corticosteroid; LABA, long-acting β 2 -agonist; laMa, longacting muscarinic antagonist.
currently available LABA/LAMA combinations and chose only approved doses of these combinations and their comparators. Including all available LABA/LAMA combinations also allowed us to provide indirect insights on the potential relative efficacy of these drugs (although we also recognize that any conclusions drawn will need to be confirmed in prospective, head-to-head studies). In addition, we used as comparators the treatments most commonly prescribed in COPD clinical practice (ie, LAMAs or LABA/ICS). Finally, we elected to implement the robust methodology of a standard meta-analysis design that involved a direct, pooled analysis of LABA/LAMA with their comparators. Based on all of the above, we believe that our analysis provides clinically relevant, high-quality evidence that is applicable to daily clinical practice. After 12 weeks of treatment, significant improvements in lung function (trough and peak 
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laBa/laMa versus laMa monotherapy or laBa/ICs in COPD treatment effects and NNTBs are similar to those of previous meta-analyses comparing LABA/LAMA with LAMA and/or LABA/ICS 10, 14 and were maintained versus both comparators after longer periods of treatments (24-26 weeks or 52 weeks). Significant improvements in peak FEV 1 relative to baseline measurements were also observed at week 12 for LABA/ LAMA treatment versus both comparators (mean differences of 0.1-0.2 L). As with trough FEV 1 , these improvements were still evident after several weeks of treatment.
Previous analyses have shown that improvements in FEV 1 are likely to be associated with improvements in patient-reported outcomes in COPD patients. 41 In our analysis, LABA/ LAMA versus LAMA alone improved the patient-reported outcomes of dyspnea (TDI) and HRQoL (SGRQ) at week 12; 28% and 14% of LABA/LAMA-versus LAMA-treated patients, respectively, were also more likely to achieve MCIDs in these outcome measures (NNTB: 26 and 16, respectively). LABA/LAMA-treated patients also had significantly reduced requirements for rescue medications during the trial than both LAMA-and LABA/ICS-treated patients. A trend in favor of LABA/LAMA versus LABA/ICS treatment was also observed with respect to TDI score and, for health status, a significant benefit in favor of LABA/LAMA was observed at week 26 but not at week 12 versus LABA/ ICS. These differences were mainly driven by the Ind/Gly trials; however, significant heterogeneity in component studies prevented firm conclusions to be drawn. As mentioned previously, LABAs improve symptoms and HRQoL more effectively than LAMAs, while LAMAs are superior to LABAs in reducing exacerbations. 9, 11 Given that the severity and frequency of exacerbations are associated with impaired HRQoL, 42 the improvements in HRQoL with LABA/LAMA versus LABA/ICS were more evident in studies including patients with more severe exacerbations. 36 A protocol-defined end point of this meta-analysis was to examine the annualized rate of COPD exacerbations prospectively collected as an efficacy end point. Only three studies (two LABA/LAMA versus LABA/ICS comparisons 35, 36 and one LABA/LAMA versus LAMA comparison 26 ) prospectively collected exacerbation rates, and therefore a meta-analysis of LABA/LAMA versus LAMA was not possible. Nevertheless, a positive signal for LABA/LAMA versus LAMA treatment was evident in the SPARK study, 26 and the inclusion of data from ongoing studies such as DYNAGITO (Tio/Olo versus Tio) will clarify the role of LABA/LAMA versus LAMA treatment in the prevention of COPD exacerbations, especially in high-risk populations. Compared with LABA/ICS, however, LABA/ LAMA treatment significantly reduced the rate of moderate and/or severe exacerbations, and a trend in favor of LABA/ LAMA was also observed for reducing severe exacerbations. Whether this finding represents an effect of Ind/Gly, which was the comparator LABA/LAMA used in the two evaluated studies, 35, 36 or an overall effect of the LABA/LAMA class needs to be defined in prospective studies using the other available combinations.
AE incidence was significantly lower in LABA/LAMAversus LABA/ICS-treated patients (NNTH =32), with the 
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laBa/laMa versus laMa monotherapy or laBa/ICs in COPD excess in the LABA/ICS arm plausibly related to the ICS component. This difference, however, did not translate through to SAEs, with no significant differences in SAE incidence observed between LABA/LAMA-and either LABA/ICS-or LAMA-treated patients. The incidence of pneumonia, however, was significantly lower in the LABA/LAMA group versus the LABA/ICS-treated patients (RR: 0.34). Several studies and systematic reviews comparing pneumonia risk in patients receiving ICS alone or in combination with LABA have reported a greater incidence of pneumonia in the LABA/ICS or ICS arms relative to the LABA arm. 5, 43 Regarding potential differences between different ICS treatments, some evidence of a higher risk of any pneumonia event has been reported with fluticasone versus budesonide, but no significant differences between the two drugs were observed in terms of SAEs (either pneumoniarelated or all-cause) or mortality. 44 In the studies included in the current analysis, salmeterol/fluticasone propionate was the only LABA/ICS used as a comparator; therefore, in our systematic review, we were not able to provide additional data in this regard.
Cardiovascular events were also of particular interest as single-agent LABAs have been associated with increased risk of arrhythmias, 45 whereas retrospective analyses of LABA/ ICS studies have shown a potential benefit for LABA/ICS on the risk of cardiovascular AEs versus placebo. 46 A recent study demonstrated that LABA/ICS did not reduce mortality versus LABA/placebo in patients with, or at risk of, cardiovascular events, 47 disputing the notion that ICS-induced decreases in systemic inflammation can reduce mortality. In the current analysis, no significant differences were observed between any of the treatment classes with respect to cardiac or cardiovascular disorders; this is in accordance with a pooled analysis of safety data showing no increase in the risk of major cardiovascular events in COPD patients treated with LABA/LAMA (Ind/Gly) versus placebo (RR: 1.04, 95% CI: [0. 45, 2.42] ). 48 Withdrawals due to AEs were significantly higher in LABA/ICS-treated patients compared with LABA/LAMAtreated patients, presumably due to AEs of pneumonia or other respiratory or extrapulmonary events associated with ICS use. Indeed, a significantly higher incidence of pneumonia (P=0.02) was observed in the LABA/ICS arm of one of the composite studies included in this meta-analysis, while a threefold higher incidence was reported in other studies. 35, 36 Withdrawals due to lack of efficacy, however, occurred in significantly more LAMA-versus LABA/LAMA-treated patients, a finding that was driven largely by two of the component trials. 26, 31 There are certain potential limitations in the current analysis. 1) Open-label tiotropium was used as comparator in some studies; 24, 26 this may have affected patient-reported outcomes (TDI and SGRQ), although it should not bias objective outcomes such as FEV 1 . 2) As our sample was largely composed of patients with stable COPD and infrequent exacerbations, our findings cannot readily be applied to all patients with frequent exacerbations; nevertheless, a significant proportion of patients with frequent exacerbations were included in the two studies that evaluated exacerbations as an outcome. 26, 36 3) In this analysis, we do not provide any comparisons of LABA/LAMA versus LABA, as we wanted to evaluate the available evidence compared with the most commonly prescribed medications for COPD, namely, LABA/ICS or LAMA. That said, however, the recent network meta-analysis by Oba and Lone 16 did include this comparison, finding LABA/LAMA combinations to be associated with significantly improved efficacy outcomes versus LABAs while maintaining similar safety profiles. 4) Based on the design of the studies identified for this systematic review, we are unable to provide data on outcomes beyond 52/64 weeks or on mortality or disease progression. Further studies using LABA/LAMA combinations are required to address these important scientific questions. 5) Given the heterogeneity of COPD, it would have been of interest to evaluate further parameters such as additional spirometric measures (eg, forced vital capacity [FVC] 49 or other markers of small airways dysfunction) or the effects of treatments on physical activity. 50, 51 Data on such parameters are, however, not uniformly presented in RCTs; therefore, in this meta-analysis, the most commonly used clinically relevant outcomes were prespecified as the outcomes of interest. 6) Definitive conclusions on the relative efficacy of different treatments within the LABA/LAMA class cannot be made as the individual treatments were not compared head to head. Nevertheless, we observed differences between different drugs, and the clinical significance of these differences needs to be further evaluated.
Conclusion
This meta-analysis of 23 RCTs provides evidence that LABA/ LAMA FDCs offer superior efficacy and comparable safety to LAMA or LABA/ICS in patients with stable moderateto-very severe COPD, indicating their potential as first-line treatment options for this population of patients.
